Expanded Access Norgine is actively expanding access programs and has announced an Expanded Access Program for DFMO, presenting a direct opportunities channel to engage patient access initiatives, payer strategy discussions, and potential partnerships with healthcare providers and advocacy groups.

Manufacturing Expansion Significant investment in UK and Northern European manufacturing capacity, including a £23 million upgrade at the Welsh site and staff expansion, signals opportunity to position supply chain, logistics services, and contract manufacturing partnerships to support increased regional demand.

Strategic Acquisitions Recent Theravia acquisition expands rare disease portfolio, opening doors for cross-sell of niche therapies, co-promotion opportunities, and channel partnerships in Europe and beyond to accelerate market access for complementary treatments.

Allied Partnerships Exclusive licensing with Vir Biotechnology for hepatitis delta treatment creates a co-promotion and distribution opportunity in Europe, Australia, and New Zealand, suggesting potential collaboration on access programs, patient support, and regulatory navigation services.

Diversified Portfolio With a broad specialty focus, in-house manufacturing, and robust supply networks, Norgine presents opportunities to offer end-to-end solutions including supply reliability, clinical/regulatory services, and lifecycle management support to healthcare systems facing supply chain volatility.